Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder (Review)
- Authors:
- Francesca Sanguedolce
- Davide Russo
- Vito Mancini
- Oscar Selvaggio
- Beppe Calo
- Giuseppe Carrieri
- Luigi Cormio
-
Affiliations: Department of Pathology, University Hospital, I‑71121 Foggia, Italy, Department of Urology and Renal Transplantation, University Hospital, I‑71121 Foggia, Italy - Published online on: December 7, 2018 https://doi.org/10.3892/mco.2018.1786
- Pages: 205-213
-
Copyright: © Sanguedolce et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Amin MB, Ro JY, el-Sharkawy T, Lee KM, Troncoso P, Silva EG, Ordóñez NG and Ayala AG: Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol. 18:1224–1232. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Amin MB, Tamboli P, Merchant SH, Ordóñez NG, Ro J, Ayala AG and Ro JY: Micropapillary component in lung adenocarcinoma: A distinctive histologic feature with possible prognostic significance. Am J Surg Pathol. 26:358–364. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Luna-Moré S, Gonzalez B, Acedo C, Rodrigo I and Luna C: Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma. Pathol Res Pract. 190:668–674. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Nagao T, Gaffey TA, Visscher DW, Kay PA, Minato H, Serizawa H and Lewis JE: Invasive micropapillary salivary duct carcinoma: A distinct histologic variant with biologic significance. Am J Surg Pathol. 28:319–326. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sakamoto K, Watanabe M, De La Cruz C, Honda H, Ise H, Mitsui K, Namiki K, Mikami Y, Moriya T and Sasano H: Primary invasive micropapillary carcinoma of the colon. Histopathology. 47:479–484. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Smith Sehdev AE, Sehdev PS and Kurman RJ: Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: A clinicopathologic analysis of 135 cases. Am J Surg Pathol. 27:725–736. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Nassar H, Pansare V, Zhang H, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J and Adsay V: Pathogenesis of invasive micropapillary carcinoma: Role of MUC1 glycoprotein. Mod Pathol. 17:1045–1050. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Nassar H: Carcinomas with micropapillary morphology: Clinical significance and current concepts. Adv Anat Pathol. 11:297–303. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sangoi AR, Beck AH, Amin MB, Cheng L, Epstein JI, Hansel DE, Iczkowski KA, Lopez-Beltran A, Oliva E, Paner GP, et al: Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol. 34:1367–1376. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL and Pisters LL: Micropapillary bladder cancer: A review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 110:62–67. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
López JI, Elorriaga K, Imaz I and Bilbao FJ: Micropapillary transitional cell carcinoma of the urinary bladder. Histopathology. 34:561–562. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Compérat E, Roupret M, Yaxley J, Reynolds J, Varinot J, Ouzaïd I, Cussenot O and Samaratunga H: Micropapillary urothelial carcinoma of the urinary bladder: A clinicopathological analysis of 72 cases. Pathology. 42:650–654. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, Jennings TA, Otto GA, Donahue A, He J, et al: A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res. 20:68–75. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Perepletchikov AM and Parwani AV: Micropapillary urothelial carcinoma: Clinico-pathologic review. Pathol Res Pract. 205:807–810. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Johansson SL, Borghede G and Holmäng S: Micropapillary bladder carcinoma: A clinicopathological study of 20 cases. J Urol. 161:1798–1802. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Paterakos M, Watkin WG, Edgerton SM, Moore DH II and Thor AD: Invasive micropapillary carcinoma of the breast: A prognostic study. Hum Pathol. 30:1459–1463. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Marchiò C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S, et al: Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol. 215:398–410. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ and Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 216:141–150. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lotan TL, Ye H, Melamed J, Wu XR, Shih IeM and Epstein JI: Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol. 33:1037–1041. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Trabelsi A, Stita W, Soumaya R, Mestiri S, Jaidene M, Mokni M and Korbi S: Micropapillary carcinoma of the urinary bladder: A case report and review of the literature. Can Urol Assoc J. 2:540–542. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Alkibay T, Sözen S, Gürocak S, Işik Gönül I, Poyraz A and Ure I: Micropapillary pattern in urothelial carcinoma: A clinicopathological analysis. Urol Int. 83:300–305. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Watts KE and Hansel DE: Emerging concepts in micropapillary urothelial carcinoma. Adv Anat Pathol. 17:182–186. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Samaratunga H and Delahunt B: Recently described and unusual variants of urothelial carcinoma of the urinary bladder. Pathology. 44:407–418. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Alvarado-Cabrero I, Sierra-Santiesteban FI, Mantilla-Morales A and Hernández-Hernandez DM: Micropapillary carcinoma of the urothelial tract. A clinicopathologic study of 38 cases. Ann Diagn Pathol. 9:1–5. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Heudel P, El Karak F, Ismaili N, Droz JP and Flechon A: Micropapillary bladder cancer: A review of Léon Bérard Cancer Center experience. BMC Urol. 9:52009. View Article : Google Scholar : PubMed/NCBI | |
|
Lopez-Beltran A, Cheng L, Raspollini MR, Canas-Marques R, Scarpelli M, Cimadamore A, Gasparrini S and Montironi R: Variants of bladder cancer: The pathologist's point of view. Eur Urol Suppl. 16:210–222. 2017. View Article : Google Scholar | |
|
Sakuma T, Furuta M, Mimura A, Tanigawa N, Takamizu R and Kawano K: Urine cytology of micropapillary carcinoma of the urinary bladder. Diagn Cytopathol. 39:852–856. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Maranchie JK, Bouyounes BT, Zhang PL, O'Donnell MA, Summerhayes IC and DeWolf WC: Clinical and pathological characteristics of micropapillary transitional cell carcinoma: A highly aggressive variant. J Urol. 163:748–751. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Amin A and Epstein JI: Noninvasive micropapillary urothelial carcinoma: A clinicopathologic study of 18 cases. Hum Pathol. 43:2124–2128. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Moch H, Humphrey PA, Ulbright TM and Reuter V: WHO Classification of Tumors of the Urinary System and Male Genital Organs. 8. 4th. IARC Press; Lyon, France: 2016 | |
|
Samaratunga H and Khoo K: Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology. 45:55–64. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Willis DL, Fernandez MI, Dickstein RJ, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, et al: Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 193:1129–1134. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang JK, Boorjian SA, Cheville JC, Kim SP, Tarrell RF, Thapa P and Frank I: Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: A matched cohort analysis. World J Urol. 30:801–806. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ching CB, Amin MB, Tubbs RR, Elson P, Platt E, Dreicer R, Fergany A and Hansel DE: HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: Analysis by dual-color in situ hybridization. Mod Pathol. 24:1111–1119. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson MK, Jeffrey Karnes R, et al: Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 27:758–764. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Patriarca C and Giunta P: Invasive micropapillary carcinoma: Beyond the borders. Am J Surg Pathol. 35:311–312. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Amin MB: Histological variants of urothelial carcinoma: Diagnostic, therapeutic and prognostic implications. Mod Pathol. 22 Suppl 2:S96–S118. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Humphrey PA: Micropapillary urothelial carcinoma of the urinary tract. J Urol. 186:1071–1072. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lopez-Beltran A, Montironi R, Blanca A and Cheng L: Invasive micropapillary urothelial carcinoma of the bladder. Hum Pathol. 41:1159–1164. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Oh YL and Kim KR: Micropapillary variant of transitional cell carcinoma of the ureter. Pathol Int. 50:52–56. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Perez-Montiel D, Wakely PE, Hes O, Michal M and Suster S: High-grade urothelial carcinoma of the renal pelvis: Clinicopathologic study of 108 cases with emphasis on unusual morphologic variants. Mod Pathol. 19:494–503. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kuroda N, Tamura M, Ohara M, Hirouchi T, Mizuno K and Miyazaki E: Invasive micropapillary carcinoma of the urinary bladder: An immunohistochemical study of neoplastic and stromal cells. Int J Urol. 13:1015–1018. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang HSR, Ali-Fehmi R and Bianco F: Characteristic immunohistochemical profiles and aggressive behavior of micropapillary and other histological variants and subtypes of urothelial carcinoma. Mod Pathol. 17 (Suppl 1):186A(782). 2014. | |
|
Ohtsuki Y, Kuroda N, Umeoka T, Watanabe R, Ochi K, Okada Y, Lee GH and Furihata M: KL-6 is another useful marker in assessing a micropapillary pattern in carcinomas of the breast and urinary bladder, but not the colon. Med Mol Morphol. 42:123–127. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sangoi AR, Higgins JP, Rouse RV, Schneider AG and McKenney JK: Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact. Mod Pathol. 22:660–667. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, et al: Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer. Eur Urol. 70:611–620. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nishizawa K, Kobayashi T, Mitsumori K, Ide Y, Watanabe J and Ogura K: Micropapillary bladder cancer. Int J Urol. 12:506–508. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kwon GY and Ro JY: Micropapillary variant of urothelial carcinoma. Adv Urol. 2011:2171532011. View Article : Google Scholar : PubMed/NCBI | |
|
Compérat E, Roupret M, Conort P, Chartier-Kastler E, Bitker MO, Richard F, Capron F, Haertig A, Cussenot O and Camparo P: Aurora-A/STK-15 is differentially expressed in the micropapillary variant of bladder cancer. Urol Int. 82:312–317. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, et al: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst. 94:1320–1329. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, Bufo P, Battaglia M, Selvaggi FP and Carrieri G: Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol. 28:285–289. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, Bufo P, Battaglia M, Selvaggi FP and Carrieri G: Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res. 29:4201–4204. 2009.PubMed/NCBI | |
|
Meeks JJ, Taylor JM, Matsushita K, Herr HW, Donat SM, Bochner BH and Dalbagni G: Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int. 111:E325–E330. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL and Pisters LL: The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 175:881–885. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhai QJ, Black J, Ayala AG and Ro JY: Histologic variants of infiltrating urothelial carcinoma. Arch Pathol Lab Med. 131:1244–1256. 2007.PubMed/NCBI | |
|
Black PC, Brown GA and Dinney CPN: The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol. 27:3–7. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, et al: Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 108:693–699. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Canvasser N, Weizer A, Crossley H, Dailey S, He C, Kunju LP, Lee C, Hafez K, Hollenbeck B, Morgan T, Montie J and Montgomery J: Micropapillary Differentiation Versus Conventional Urothelial Carcinoma: Effects Of Neoadjuvant Chemotherapy And Cystectomy On Survival. AUA 2014 conference. abstract MP50-06. | |
|
Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, et al: Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 119:684–691. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI and Weinberg RA: The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 312:513–516. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Tschui J, Vassella E, Bandi N, Baumgartner U, Genitsch V, Rotzer D, Seiler R, Thalmann GN and Fleischmann A: Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Arch. 466:703–710. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zwick E, Bange J and Ullrich A: Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 8:161–173. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr and Le XF: HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: Implications for HER2-targeted antibody therapy. Oncogene. 25:6986–6996. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Scholl S, Beuzeboc P and Pouillart P: Targeting HER2 in other tumor types. Ann Oncol. 12 Suppl 1:S81–S87. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hansel DE, Swain E, Dreicer R and Tubbs RR: HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol. 130:274–281. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Eissa S, Ali HS, Al Tonsi AH, Zaglol A and El Ahmady O: HER2/neu expression in bladder cancer: Relationship to cell cycle kinetics. Clin Biochem. 38:142–148. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tolmachev V: Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 14:2999–3019. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Gandour-Edwards R, Lara PN Jr, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ and DeVere-White R: Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 95:1009–1015. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Tinoco G, Warsch S, Glück S, Avancha K and Montero AJ: Treating breast cancer in the 21st century: Emerging biological therapies. J Cancer. 4:117–132. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Smyth EC and Cunningham D: Targeted therapy for gastric cancer. Curr Treat Options Oncol. 13:377–389. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 open-label randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P and Vieillefond A: Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients. Ann Oncol. 21:815–819. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Underwood M, Bartlett J, Reeves J, Gardiner DS, Scott R and Cooke T: C-erbB-2 gene amplification: A molecular marker in recurrent bladder tumors? Cancer Res. 55:2422–2430. 1995.PubMed/NCBI | |
|
Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP and Sauter G: Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 5:1966–1975. 1999.PubMed/NCBI | |
|
Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA and Bartlett JM: HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: A role for anti-HER2 therapy? Eur J Cancer. 40:56–63. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ehsani L and Osunkoya AO: Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: Correlation with clinicopathologic parameters. Int J Clin Exp Pathol. 7:2544–2550. 2014.PubMed/NCBI | |
|
Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, et al: National Cancer Institute: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 25:2218–2224. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Caner V, Turk NS, Duzcan F, Tufan NL, Kelten EC, Zencir S, Dodurga Y, Bagci H and Duzcan SE: No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res. 14:261–266. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G and Insabato L: Role of polysomy 17 in transitional cell carcinoma of the bladder: Immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol. 17:198–205. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li B, Kanamaru H, Noriki S, Fukuda M and Okada K: Numeric aberration of chromosome 17 is strongly correlated with p53 overexpression, tumor proliferation and histopathology in human bladder cancer. Int J Urol. 5:317–323. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue T, Sato K, Tsuchiya N, Matsuura S, Iinuma M, Habuchi T and Kato T: Numeric aberrations of HER-2 and chromosome 17 detected by fluorescence in situ hybridization in urine-exfoliated cells from patients with urothelial carcinoma. Urology. 64:617–621. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, Vasou O, Ntinis A, Michalopoulou F, Moreas I, Koutselini H, et al: Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research. J BUON. 14:457–462. 2009.PubMed/NCBI | |
|
Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, Okuhara E, Akiyama T, Toyoshima K, Yamamoto T, et al: An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer. 70:2493–2498. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr and Grignon DJ: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 7:2440–2447. 2001.PubMed/NCBI | |
|
Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI and Lotan Y: Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 106:1216–1222. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Naruse K, Yamada Y, Nakamura K, Aoki S, Taki T, Zennami K, Katsuda R, Watanabe M, Nishikawa G, Itoh Y, et al: Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder. Oncol Rep. 23:1577–1583. 2010.PubMed/NCBI | |
|
Charfi S, Khabir A, Mnif H, Ellouze S, Nabil Mhiri M and Boudawara-Sellami T: Immunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation with p53 and p63 expression. J Microsc Ultrastruct. 1:17–21. 2013. View Article : Google Scholar | |
|
Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, Sayk F, Feller AC and Böhle A: HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications. Int J Cancer. 102:514–518. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Jackson CL, Yang D, Noble L, Wheeler M, MacKenzie D, Adegun T and Amin A: Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma. Target Oncol. 10:355–363. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim B, Kim G, Song B, Lee C, Park JH and Moon KC: HER2 protein over- expression and gene amplification in plasmacytoid urothelial carcinoma of the urinary bladder. Dis Markers. 6:20162016. | |
|
Miyama Y, Morikawa T, Nakagawa T, Homma Y and Fukayama M: Lipid cell and micropapillary variants of urothelial carcinoma of the ureter. Case Rep Oncol. 8:515–519. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, Chew K, Mihatsch MJ, Gudat F and Waldman F: Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 53:2199–2203. 1993.PubMed/NCBI | |
|
Coogan CL, Estrada CR, Kapur S and Bloom KJ: HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology. 63:786–790. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Behzatoğlu K, Yörükoğlu K, Demir H and Bal N: Human epidermal growth factor receptor 2 overexpression in micropapillary and other variants of urothelial carcinoma. Eur Urol Focus. Jun 21–2016.(Epub ahead of print). | |
|
Makise N, Morikawa T, Takeshima Y, Fujimura T, Homma Y and Fukayama M: Urinary bladder urothelial carcinoma with concurrent plasmacytoid and micropapillary differentiations: A report of two cases with an emphasis on serum carbohydrate antigen 19-9. Pathol Int. 65:495–500. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Goodman AL and Osunkoya AO: Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: An analysis of 27 cases. Hum Pathol. 57:160–164. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
El Ochi MR, Oukabli M, Bouaiti E, Chahdi H, Boudhas A, Allaoui M, Ameur A, Abbar M and Al Bouzidi A: Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. BMC Clin Pathol. 17:32017. View Article : Google Scholar : PubMed/NCBI | |
|
Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, et al: Prognostic value of molecular breast cancer subtypes based on Her2, ESR1, PGR and Ki67 mRNA-expression in muscle invasive bladder cancer. Transl Oncol. 11:467–476. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al: Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 36:2105–2122. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA and Bartlett JM: HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer. 89:1305–1309. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hynes NE and Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1198:165–184. 1994.PubMed/NCBI | |
|
Knowles MA and Hurst CD: Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ross JS, Wang K, Khaira D, Ali SM, Fisher HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, et al: Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 122:702–711. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Pétavy F and El-Hariry IA: A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 115:2881–2890. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mercogliano MF, Inurrigarro G, De Martino M, Venturutti L, Rivas MA, Cordo-Russo R, Proietti CJ, Fernández EA, Frahm I, Barchuk S, et al: Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer. BMC Cancer. 17:8952017. View Article : Google Scholar : PubMed/NCBI |
